7 hallmark features of anxiety disorders

Slideshow

Affecting between 15% to 20% of children and adolescents, anxiety disorders are the most prevalent psychiatric condition in pediatrics. The impact can be significant with difficulties in social and academic functioning as well as increased risk for other mental health concerns. However, it can be difficult for a clinician to differentiate between anxiety and an anxiety disorder. Here are 7 signs to help make the diagnosis.

Recent Videos
Diet, mental health, and pediatric nutrition, with Colleen Sloan, PA-C, RDN
Victor Carrion, MD
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Supporting mental health in pediatric primary care with Victor Carrion, MD
Discussing social media and potential nutrition impacts with Colleen Sloan, PA-C, RDN
Jenna Marcovitz, MA explains how music therapy helps in pediatric care
Related Content
Rise in pediatric firearm deaths linked to permissive state gun laws | Image Credit: © Александра Замулина- stock.adobe.com.

Rise in pediatric firearm deaths linked to permissive state gun laws

Morgan Ebert, Managing Editor
June 11th 2025
Article

New research highlights how differences in state laws may be linked to changing trends in pediatric firearm mortality across the United States.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
First infant enrolled in trial of roflumilast 0.05% for atopic dermatitis in infants | | Image Credit: © Dinko - © Dinko- stock.adobe.com.

First infant enrolled in trial of roflumilast cream, 0.05% for atopic dermatitis in infants

Joshua Fitch, Senior Editor
June 10th 2025
Article

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA approves clesrovimab to protect infants during first RSV season | Image Credit: Contemporary Pediatrics

FDA approves clesrovimab to protect infants during first RSV season

Joshua Fitch, Senior Editor
June 9th 2025
Article

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

Dupilumab improves atopic dermatitis severity in adolescents, adults with skin of color | Image Credit: © this_baker - © this_baker - stock.adobe.com.

Dupilumab improves atopic dermatitis severity in adolescents, adults with skin of color

Joshua Fitch, Senior Editor
June 9th 2025
Article

Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), trial's primary endpoint.

© 2025 MJH Life Sciences

All rights reserved.